The Noscapine Chronicle: A Pharmaco-Historic Biography of the Opiate Alkaloid Family and its Clinical Applications

Medicinal Research Reviews

Volumn 35, Issue 5, 2015, Pages 1072-1096

  Rida, Padmashree C G ^a,b   Livecche, Dillon ^b   Ogden, Angela ^b   Zhou, Jun ^c   Aneja, Ritu ^b  

^a Novazoi Theranostics   (United States)

^b GEORGIA STATE UNIVERSITY   (United States)

^c NANKAI UNIVERSITY   (China)

Author keywords

Antineoplastic drugs; Centrosome declustering drugs; Microtubule targeting drugs; Noscapine; Noscapinoids

Indexed keywords

ANTIMALARIAL AGENT; ANTITUSSIVE AGENT; NOSCAPINE; WARFARIN; ALKALOID; ANTINEOPLASTIC AGENT; PLANT EXTRACT;

ANTIMALARIAL ACTIVITY; ANTINEOPLASTIC ACTIVITY; ARTICLE; BIOSYNTHESIS; BREAST CANCER; CENTROSOME; CEREBROVASCULAR ACCIDENT; CLINICAL TRIAL (TOPIC); DRUG DESIGN; DRUG POTENCY; DRUG PURIFICATION; DRUG SAFETY; DRUG SYNTHESIS; GLIOBLASTOMA; HUMAN; INTRACELLULAR SIGNALING; MITOSIS SPINDLE; NON SMALL CELL LUNG CANCER; NONHUMAN; OVARY CANCER; OVARY POLYCYSTIC DISEASE; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PROSTATE CANCER; SIDE EFFECT; STOMACH CANCER; THYMOMA; ANIMAL; CHEMISTRY; DRUG EFFECTS; FEMALE; MALE; MEDICINAL CHEMISTRY; MICROTUBULE; NEOPLASMS; PAPAVER; PRECLINICAL STUDY; PROCEDURES; STROKE;

ALKALOIDS; ANIMALS; ANTINEOPLASTIC AGENTS; CENTROSOME; CHEMISTRY, PHARMACEUTICAL; DRUG EVALUATION, PRECLINICAL; FEMALE; HUMANS; MALE; MICROTUBULES; NEOPLASMS; NOSCAPINE; PAPAVER; PLANT EXTRACTS; STROKE; WARFARIN;

EID: 84938596259     PISSN: 01986325     EISSN: 10981128     Source Type: Journal    
DOI: 10.1002/med.21357     Document Type: Article

References (107)

1. Hogshire J. Opium for the Masses: Harvesting Nature's Best Pain Medication. Feral House, Port Townsend, WA; 2009.
2. Ainsworth S. Opium, into the arms of Morpheus. Nurse Prescribing 2013;11(8):376-376.
3. Institute MR. Noscapine: A Safe Cough Suppressant with Newly Discovered Effects in Treating Cancer and Stroke. 2007. http://www.pcref.org/MedInsight%20-%20PCREF%20Noscapine%20Review.pdf.
4. Wisniak J. Pierre-Jean Robiquet. Educ Quim 2013;24(1):139-149.
5. Chopra RN, Knowles R. The action of opium and narcotine in malaria. Indian J Med Res 1930;18(1):5-13.
6. National Center for Biotechnology Information. PubChem Compound Database; CID=275196, https://pubchem.ncbi.nlm.nih.gov/compound/275196 (accessed June 30, 2015).
7. The Merck Index. 9th ed. Rahway, New Jersey: Merck & Co., Inc., 1976., p. 872.
8. Robiquet P. Note sur la Narcotine. J Pharm 1831;17:637-643.
9. Dang TTT, Facchini PJ. Characterization of Three O-Methyltransferases Involved in Noscapine Biosynthesis in Opium Poppy. Plant Physiol 2012;159(2):618-631.
10. Dang TT, Facchini PJ. CYP82Y1 is N-methylcanadine 1-hydroxylase, a key noscapine biosynthetic enzyme in opium poppy. J Biol Chem 2014;289(4):2013-2026.
11. Dang TT, Facchini PJ. Cloning and characterization of canadine synthase involved in noscapine biosynthesis in opium poppy. FEBS Lett 2014;588(1):198-204.
12. Dang TT, Chen X, Facchini PJ. Acetylation serves as a protective group in noscapine biosynthesis in opium poppy. Nat Chem Biol 2015;11(2):104-106.
13. Winzer T, Gazda V, He Z, Kaminski F, Kern M, Larson TR, Li Y, Meade F, Teodor R, Vaistij FE, Walker C, Bowser TA, Graham IA. A Papaver somniferum 10-gene cluster for synthesis of the anticancer alkaloid noscapine. Science 2012;336(6089):1704-1708.
14. Chen X, Facchini PJ. Short-chain dehydrogenase/reductase catalyzing the final step of noscapine biosynthesis is localized to laticifers in opium poppy. Plant J 2014;77(2):173-184.
15. Institute MR. Noscapine a safe cough suppressant with newly discovered effects in treating cancer and stroke. 2007.
16. Vree TB, vanDongen RT, Koopman-Kimenai PM. Codeine analgesia is due to codeine-6-glucuronide, not morphine. Int J Clin Pract 2000;54(6):395-398.
17. Boyer E. Management of opioid analgesic overdose. N Engl J Med 2012;367:146-155.
18. Kamei, J. Role of Opioidergic and Serotonergic Mechanisms in Cough and Antitussives. Pulmonary Pharmacology 1996;9:349-356.
19. Mahmoudian M, Aboutaleb N, Beiranvand F, Moazzam A-A, Shafiei M. Noscapine antagonizes vasoconstrictor action of bradykinin in isolated human umbilical artery. Med J Islam Repub Iran 2011;25(2):82-86.
20. Mooraki A, Jenabi A, Jabbari M, Zolfaghari MI, Javanmardi SZ, Mahmoudian M, Bastani B. Noscapine suppresses angiotensin converting enzyme inhibitors-induced cough. Nephrology 2005;10(4):348-350.
21. Mahmoudian M, Mehrpour M, Benaissa F, Siadatpour Z. A preliminary report on the application of noscapine in the treatment of stroke. Eur J Clin Pharmacol 2003;59(8-9):579-581.
22. Bonita R. Epidemiology of stroke. Lancet 1992;339(8789):342-344.
23. Francel PC. Bradykinin and neuronal injury. J Neurotrauma 1992;9(Suppl 1):S27-S45.
24. Khanmoradi M, Ali Mard S, Aboutaleb N, Nobakht M, Mahmoudian M. The protective activity of noscapine on renal ischemia-reperfusion injury in male Wistar rat. Iran J Basic Med Sci 2014;17(4):244-249.
25. Ke Y, Ye K, Grossniklaus HE, Archer DR, Joshi HC, Kapp JA. Noscapine inhibits tumor growth with little toxicity to normal tissues or inhibition of immune responses. Cancer Immunol Immunother 2000;49(4-5):217-225.
26. Ye K, Ke Y, Keshava N, Shanks J, Kapp JA, Tekmal RR, Petros J, Joshi HC. Opium alkaloid noscapine is an antitumor agent that arrests metaphase and induces apoptosis in dividing cells. Proc Natl Acad Sci USA 1998;95(4):1601-1606.
27. Zhou J, Panda D, Landen JW, Wilson L, Joshi HC. Minor alteration of microtubule dynamics causes loss of tension across kinetochore pairs and activates the spindle checkpoint. J Biol Chem 2002;277(19):17200-17208.
28. Aneja R, Zhou J, Zhou B, Chandra R, Joshi HC. Treatment of hormone-refractory breast cancer: Apoptosis and regression of human tumors implanted in mice. Mol Cancer Ther 2006;5(9):2366-2377.
29. Tormoehlen LM, Pascuzzi RM. Thymoma, myasthenia gravis, and other paraneoplastic syndromes. Hematol Oncol Clin North Am 2008;22(3):509-526.
30. Ye K, Ke Y, Keshava N, Shanks J, Kapp JA, Tekmal RR, Petros J, Joshi HC. Opium alkaloid noscapine is an antitumor agent that arrests metaphase and induces apoptosis in dividing cells. Proceedings of the National Academy of Sciences of the United States of America 1998;95(4):1601-1606.
31. Zhou J, Gupta K, Yao J, Ye K, Panda D, Giannakakou P, Joshi HC. Paclitaxel-resistant human ovarian cancer cells undergo c-Jun NH2-terminal kinase-mediated apoptosis in response to noscapine. J Biol Chem 2002;277(42):39777-39785.
32. Rahbar-Roshandel N SS, Motamen A, Mahmoudian M. Noscapine reverses doxorubicin and vincristine resistance in OVCAR3 cell line. Iranian J Pharmacol Ther 2008.
33. Shen W, Liang B, Yin J, Li X, Cheng J. Noscapine increases the sensitivity of drug-resistant ovarian cancer cell line SKOV3/DDP to cisplatin by regulating cell cycle and activating apoptotic pathways. Cell Biochem Biophys 2014.
34. Mahmoudian M, Rahimi-Moghaddam P. The anti-cancer activity of noscapine: a review. Recent Pat Anticancer Drug Discov 2009;4(1):92-97.
35. Su W, Huang L, Ao Q, Zhang Q, Tian X, Fang Y, Lu Y. Noscapine sensitizes chemoresistant ovarian cancer cells to cisplatin through inhibition of HIF-1alpha. Cancer Lett 2011;305(1):94-99.
36. Landen JW, Hau V, Wang M, Davis T, Ciliax B, Wainer BH, VanMeir EG, Glass JD, Joshi HC, Archer DR. Noscapine crosses the blood-brain barrier and inhibits glioblastoma growth. Clin Cancer Res 2004;10(15):5187-5201.
37. Madan J, Pandey RS, Jain V, Katare OP, Chandra R, Katyal A. Poly (ethylene)-glycol conjugated solid lipid nanoparticles of noscapine improve biological half-life, brain delivery and efficacy in glioblastoma cells. Nanomedicine 2013;9(4):492-503.
38. Verma AK, Bansal S, Singh J, Tiwari RK, Kasi Sankar V, Tandon V, Chandra R. Synthesis and in vitro cytotoxicity of haloderivatives of noscapine. Bioorg Med Chem 2006;14(19):6733-6736.
39. Altinoz MA, Bilir A, Del Maestro RF, Tuna S, Ozcan E, Gedikoglu G. Noscapine and diltiazem augment taxol and radiation-induced S-phase arrest and clonogenic death of C6 glioma in vitro. Surg Neurol 2006;65:478-485.
40. Qi Q, Liu X, Li S, Joshi HC, Ye K. Synergistic suppression of noscapine and conventional chemotherapeutics on human glioblastoma cell growth. Acta Pharmacol Sin 2013;34(7):930-938.
41. Jhaveri N, Cho H, Torres S, Wang W, Schonthal AH, Petasis NA, Louie SG, Hofman FM, Chen TC. Noscapine inhibits tumor growth in TMZ-resistant gliomas. Cancer Lett 2011;312(2):245-252.
42. Erguven M, Bilir A, Yazihan N, Ermis E, Sabanci A, Aktas E, Aras Y, Alpman V. Decreased therapeutic effects of noscapine combined with imatinib mesylate on human glioblastoma in vitro and the effect of midkine. Cancer Cell Int 2011;11(1):18.
43. Newcomb EW, Lukyanov Y, Alonso-Basanta M, Esencay M, Smirnova I, Schnee T, Shao Y, Devitt ML, Zagzag D, McBride W, Formenti SC. Antiangiogenic effects of noscapine enhance radioresponse for GL261 tumors. Int J Radiat Oncol Biol Phys 2008;71(5):1477-1484.
44. Jackson T, Chougule MB, Ichite N, Patlolla RR, Singh M. Antitumor activity of noscapine in human non-small cell lung cancer xenograft model. Cancer Chemother Pharmacol 2008;63(1):117-126.
45. Li S, He J, Li S, Cao G, Tang S, Tong Q, Joshi HC. Noscapine induced apoptosis via downregulation of survivin in human neuroblastoma cells having wild type or null p53. PLoS One 2012;7(7):e40076.
46. Chougule M, Patel AR, Sachdeva P, Jackson T, Singh M. Anticancer activity of noscapine, an opioid alkaloid in combination with cisplatin in human non-small cell lung cancer. Lung Cancer 2011;71(3):271-282.
47. Chougule MB, Patel A, Sachdeva P, Jackson T, Singh M. Enhanced anticancer activity of gemcitabine in combination with noscapine via antiangiogenic and apoptotic pathway against non-small cell lung cancer. PLoS One 2011;6(11):e27394.
48. Madan J, Pandey RS, Jain UK, Katare OP, Aneja R, Katyal A. Sterically stabilized gelatin microassemblies of noscapine enhance cytotoxicity, apoptosis and drug delivery in lung cancer cells. Colloids Surf B Biointerfaces 2013;107:235-244.
49. Liu M, Luo XJ, Liao F, Lei XF, Dong WG. Noscapine induces mitochondria-mediated apoptosis in gastric cancer cells in vitro and in vivo. Cancer Chemother Pharmacol 2011;67(3):605-612.
50. Aneja R, Ghaleb AM, Zhou J, Yang VW, Joshi HC. p53 and p21 determine the sensitivity of noscapine-induced apoptosis in colon cancer cells. Cancer Res 2007;67(8):3862-3870.
51. Yang ZR, Liu M, Peng XL, Lei XF, Zhang JX, Dong WG. Noscapine induces mitochondria-mediated apoptosis in human colon cancer cells in vivo and in vitro. Biochem Biophys Res Commun 2012;421(3):627-633.
52. Barken I, Geller J, Rogosnitzky M. Noscapine inhibits human prostate cancer progression and metastasis in a mouse model. Anticancer Res 2008;28(6a):3701-3704.
53. Pannu V, Karna P, Sajja HK, Shukla D, Aneja R. Synergistic antimicrotubule therapy for prostate cancer. Biochem Pharmacol 2011;81(4):478-487.
54. Chougule MB, Patel AR, Jackson T, Singh M. Antitumor activity of noscapine in combination with doxorubicin in triple negative breast cancer. PLoS One 2011;6(3):e17733.
55. Madan J, Gundala SR, Kasetti Y, Bharatam PV, Aneja R, Katyal A, Jain UK. Enhanced noscapine delivery using estrogen-receptor-targeted nanoparticles for breast cancer therapy. Anticancer Drugs 2014;25(6):704-716.
56. Shin JS, Lee SS, Lee MK. Inhibitory effects of noscapine on dopamine biosynthesis in PC12 cells. Arch Pharm Res 1997;20(5):510-512.
57. Priyadarshani A, Chuttani K, Mittal G, Bhatnagar A. Radiolabeling, biodistribution and gamma scintigraphy of noscapine hydrochloride in normal and polycystic ovary induced rats. J Ovarian Res 2010;3:10.
58. Matthews JD, Morgan R, Sleigher C, Frey TK. Do viruses require the cytoskeleton? Virol J 2013;10(121):121-125.
59. Dahlstrom B, Mellstrand T, Lofdahl CG, Johansson M. Pharmacokinetic properties of noscapine. Eur J Clin Pharmacol 1982;22(6):535-539.
60. Karlsson MO, Dahlstrom B, Eckernas SA, Johansson M, Alm AT. Pharmacokinetics of oral noscapine. Eur J Clin Pharmacol 1990;39(3):275-279.
61. Aneja R, Dhiman N, Idnani J, Awasthi A, Arora SK, Chandra R, Joshi HC. Preclinical pharmacokinetics and bioavailability of noscapine, a tubulin-binding anticancer agent. Cancer Chemother Pharmacol 2007;60(6):831-839.
62. Madan J, Dhiman N, Parmar VK, Sardana S, Bharatam PV, Aneja R, Chandra R, Katyal A. Inclusion complexes of noscapine in beta-cyclodextrin offer better solubility and improved pharmacokinetics. Cancer Chemother Pharmacol 2010;65(3):537-548.
63. Chougule MB, Patel AR, Patlolla R, Jackson T, Singh M. Epithelial transport of noscapine across cell monolayer and influence of absorption enhancers on in vitro permeation and bioavailability: Implications for intestinal absorption. J Drug Target 2014;22(6):498-508.
64. Fang ZZ, Krausz KW, Li F, Cheng J, Tanaka N, Gonzalez FJ. Metabolic map and bioactivation of the anti-tumour drug noscapine. Brit J Pharmacol 2012;167(6):1271-1286.
65. Ye K, Zhou J, Landen JW, Bradbury EM, Joshi HC. Sustained activation of p34(cdc2) is required for noscapine-induced apoptosis. J Biol Chem 2001;276(50):46697-46700.
66. Sung B, Ahn KS, Aggarwal BB. Noscapine, a benzylisoquinoline alkaloid, sensitizes leukemic cells to chemotherapeutic agents and cytokines by modulating the NF-kappaB signaling pathway. Cancer Res 2010;70(8):3259-3268.
67. Kach J, Sandbo N, La J, Denner D, Reed EB, Akimova O, Koltsova S, Orlov SN, Dulin NO. Antifibrotic effects of noscapine through activation of prostaglandin E2 receptors and protein kinase A. J Biol Chem 2014;289(11):7505-7513.
68. Lasagna L, Owens AH, Jr., Shnider BI, Gold GL. Toxicity after large doses of noscapine. Cancer Chemother Rep 1961;15:33-34.
69. Ohlsson S, Holm L, Myrberg O, Sundström A, Yue Q-Y. Noscapine may increase the effect of warfarin. Brit J Clin Pharmacol 2008;65(2):277-278.
70. Fang Z-Z, Zhang Y-Y, Ge G-B, Huo H, Liang S-C, Yang L. Time-dependent inhibition (TDI) of CYP3A4 and CYP2C9 by noscapine potentially explains clinical noscapine-warfarin interaction. Brit J Clin Pharmacol 2010;69(2):193-199.
71. Zhang N, Seguin RP, Kunze KL, Zhang YY, Jeong H. Characterization of inhibition kinetics of (S)-warfarin hydroxylation by noscapine: implications in warfarin therapy. Drug Metab Dispos 2013;41(12):2114-2123.
72. Ogden A, Cheng A, Rida PC, Pannu V, Osan R, Clewley R, Aneja R. Quantitative multi-parametric evaluation of centrosome declustering drugs: centrosome amplification, mitotic phenotype, cell cycle and death. Cell Death Dis 2014;5:e1204.
73. Lopus M, Naik PK. Taking aim at a dynamic target: Noscapinoids as microtubule-targeted cancer therapeutics. Pharmacol Rep 2015;67(1):56-62.
74. Alisaraie L, Tuszynski JA. Determination of noscapine's localization and interaction with the tubulin-alpha/beta heterodimer. Chem Biol Drug Des 2011;78(4):535-546.
75. Karna P, Zughaier S, Pannu V, Simmons R, Narayan S, Aneja R. Induction of reactive oxygen species-mediated autophagy by a novel microtubule-modulating agent. J Biol Chem 2010;285(24):18737-18748.
76. Pannu V, Rida PC, Ogden A, Clewley R, Cheng A, Karna P, Lopus M, Mishra RC, Zhou J, Aneja R. Induction of robust de novo centrosome amplification, high-grade spindle multipolarity and metaphase catastrophe: A novel chemotherapeutic approach. Cell Death Dis 2012;3:e346.
77. Madan J, Gundala SR, Baruah B, Nagaraju M, Yates C, Turner T, Rangari V, Hamelberg D, Reid MD, Aneja R. Cyclodextrin complexes of reduced bromonoscapine in guar gum microspheres enhance colonic drug delivery. Mol Pharm 2014;11(12):4339-4349.
78. Naik PK, Santoshi S, Rai A, Joshi HC. Molecular modeling and competition binding study of Br-noscapine and colchicine provides insight into noscapinoid-tubulin binding site. J Mol Graph Model 2011;29(7):947-955.
79. Zughaier S, Karna P, Stephens D, Aneja R. Potent anti-inflammatory activity of novel microtubule-modulating brominated noscapine analogs. PLoS One 2010;5(2):e9165.
80. Debono AJ, Mistry SJ, Xie J, Muthiah D, Phillips J, Ventura S, Callaghan R, Pouton CW, Capuano B, Scammells PJ. The synthesis and biological evaluation of multifunctionalised derivatives of noscapine as cytotoxic agents. ChemMedChem 2014;9(2):399-410.
81. Zhou J, Gupta K, Aggarwal S, Aneja R, Chandra R, Panda D, Joshi HC. Brominated derivatives of noscapine are potent microtubule-interfering agents that perturb mitosis and inhibit cell proliferation. Mol Pharmacol 2003;63(4):799-807.
82. Aneja R, Vangapandu SN, Lopus M, Viswesarappa VG, Dhiman N, Verma A, Chandra R, Panda D, Joshi HC. Synthesis of microtubule-interfering halogenated noscapine analogs that perturb mitosis in cancer cells followed by cell death. Biochem Pharmacol 2006;72(4):415-426.
83. Aneja R, Miyagi T, Karna P, Ezell T, Shukla D, Vij Gupta M, Yates C, Chinni SR, Zhau H, Chung LW, Joshi HC. A novel microtubule-modulating agent induces mitochondrially driven caspase-dependent apoptosis via mitotic checkpoint activation in human prostate cancer cells. Eur J Cancer 2010;46(9):1668-1678.
84. Madan J, Baruah B, Nagaraju M, Abdalla MO, Yates C, Turner T, Rangari V, Hamelberg D, Aneja R. Molecular cycloencapsulation augments solubility and improves therapeutic index of brominated noscapine in prostate cancer cells. Mol Pharm 2012;9(5):1470-1480.
85. Jyoti K, Kaur K, Pandey RS, Jain UK, Chandra R, Madan J. Inhalable nanostructured lipid particles of 9-bromo-noscapine, a tubulin-binding cytotoxic agent: Invitro and in vivo studies. J Colloid Interface Sci 2015;445C:219-230.
86. Porcu E, Sipos A, Basso G, Hamel E, Bai R, Stempfer V, Udvardy A, Benyei AC, Schmidhammer H, Antus S, Viola G. Novel 9'-substituted-noscapines: Synthesis with Suzuki cross-coupling, structure elucidation and biological evaluation. Eur J Med Chem 2014;84:476-490.
87. Aneja R, Vangapandu SN, Lopus M, Chandra R, Panda D, Joshi HC. Development of a novel nitro-derivative of noscapine for the potential treatment of drug-resistant ovarian cancer and T-cell lymphoma. Mol Pharmacol 2006;69(6):1801-1809.
88. Beck WT, Cirtain MC. Continued expression of vinca alkaloid resistance by CCRF-CEM cells after treatment with tunicamycin or pronase. Cancer Res 1982;42(1):184-189.
89. Morgan SE, Kim R, Wang PC, Bhat UG, Kusumoto H, Lu T, Beck WT. Differences in mutant p53 protein stability and functional activity in teniposide-sensitive and -resistant human leukemic CEM cells. Oncogene 2000;19(43):5010-5019.
90. Santoshi S, Naik PK. Molecular insight of isotypes specific beta-tubulin interaction of tubulin heterodimer with noscapinoids. J Comput Aided Mol Des 2014;28(7):751-763.
91. Bennani YL, Gu W, Canales A, Díaz FJ, Eustace BK, Hoover RR, Jiménez-Barbero J, Nezami A, Wang T. Tubulin binding, protein-bound conformation in solution, and antimitotic cellular profiling of noscapine and its derivatives. J Med Chem 2012;55(5):1920-1925.
92. Naik PK, Chatterji BP, Vangapandu SN, Aneja R, Chandra R, Kanteveri S, Joshi HC. Rational design, synthesis and biological evaluations of amino-noscapine: A high affinity tubulin-binding noscapinoid. J Comput Aided Mol Des 2011;25(5):443-454.
93. DeBono AJ, Xie JH, Ventura S, Pouton CW, Capuano B, Scammells PJ. Synthesis and biological evaluation of N-substituted noscapine analogues. ChemMedChem 2012;7(12):2122-2133.
94. Mishra RC, Karna P, Gundala SR, Pannu V, Stanton RA, Gupta KK, Robinson MH, Lopus M, Wilson L, Henary M, Aneja R. Second generation benzofuranone ring substituted noscapine analogs: Synthesis and biological evaluation. Biochem Pharmacol 2011;82(2):110-121.
95. Manchukonda NK, Naik PK, Sridhar B, Kantevari S. Synthesis and biological evaluation of novel biaryl type alpha-noscapine congeners. Bioorg Med Chem Lett 2014;24(24):5752-5757.
96. Manchukonda NK, Naik PK, Santoshi S, Lopus M, Joseph S, Sridhar B, Kantevari S. Rational design, synthesis, and biological evaluation of third generation alpha-noscapine analogues as potent tubulin binding anti-cancer agents. PLoS One 2013;8(10):e77970.
97. Santoshi S, Manchukonda NK, Suri C, Sharma M, Sridhar B, Joseph S, Lopus M, Kantevari S, Baitharu I, Naik PK. Rational design of biaryl pharmacophore inserted noscapine derivatives as potent tubulin binding anticancer agents. J Comput Aided Mol Des 2014.
98. Winter CA, Flataker L. Toxicity studies on noscapine. Toxicol Appl Pharmacol 1961;3(1):96-106.
99. Sneyd JR. Papaveretum in women of childbearing potential. Brit Med J 1991;303(6806):852-852.
100. Noscapine. J Am Med Assoc 1958;167(8):993-994.
101. Mitchell ID, Carlton JB, Chan MY, Robinson A, Sunderland J. Noscapine-induced polyploidy in vitro. Mutagenesis 1991;6(6):479-486.
102. Singh H, Singh P, Kumari K, Chandra A, Dass SK, Chandra R. A review on noscapine, and its impact on heme metabolism. Curr Drug Metab 2013;14(3):351-360.
103. Henary M, Narayana L, Ahad S, Gundala SR, Mukkavilli R, Sharma V, Owens EA, Yadav Y, Nagaraju M, Hamelberg D, Tandon V, Panda D, Aneja R. Novel third-generation water-soluble noscapine analogs as superior microtubule-interfering agents with enhanced antiproliferative activity. Biochem Pharmacol 2014;92(2):192-205.
104. Chandra R, Madan J, Singh P, Chandra A, Kumar P, Tomar V, Dass SK. Implications of nanoscale based drug delivery systems in delivery and targeting tubulin binding agent, noscapine in cancer cells. Curr Drug Metab 2012;13(10):1476-1483.
105. Madan J, Dhiman N, Sardana S, Aneja R, Chandra R, Katyal A. Long-circulating poly(ethylene glycol)-grafted gelatin nanoparticles customized for intracellular delivery of noscapine: Preparation, in-vitro characterization, structure elucidation, pharmacokinetics, and cytotoxicity analyses. Anticancer Drugs 2011;22(6):543-555.
106. Sebak S, Mirzaei M, Malhotra M, Kulamarva A, Prakash S. Human serum albumin nanoparticles as an efficient noscapine drug delivery system for potential use in breast cancer: Preparation and in vitro analysis. Int J Nanomed 2010;5:525-532.
107. Abdalla MO, Aneja R, Dean D, Rangari V, Russell A, Jaynes J, Yates C, Turner T. Synthesis and characterization of noscapine loaded magnetic polymeric nanoparticles. J Magn Magn Mater 2010;322(2):190-196.